Immunocore Holdings plc
corporate_fare Company Profile
Immunocore Holdings plc (NASDAQ:IMCR) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 13 items for IMCR at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-06, rated 7/10. Across its 13 most recent items scored 7 or higher, the top rating is 9/10, with 7 rated 8 or above. Recent SEC coverage for IMCR spans 10-Q, 8-K, 10-K.
Recent high-impact activity:
- Brenetafusp-KIMMTRAK Combo Shows 70% Two-Year Survival in Metastatic Uveal Melanoma
- Immunocore Q3: KIMMTRAK Sales $102.2M, Net Loss Widens to $14.2M, TEBE-AM Data Slips to Q2 2027
- Immunocore Q3 Sales Dip to $102.2M; TEBE-AM Data Pushed to Q2 2027
- KIMMTRAK Q3 Sales Slip to $102.2M as Net Loss Widens to $14.2M
- Immunocore Completes Enrollment in Pivotal TEBE-AM Melanoma Trial, Data Expected by End of 2026
Financial Snapshot
Short Interest & Short Volume
14.21 days to coverFINRA reported short interest of 7,793,995 shares in IMCR as of the October 30, 2026 settlement, a 0.1% decrease from the prior period — about 14.2 days to cover at its recent average daily volume. On November 20, 2026, 19.6% of IMCR volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.